Introduction {#s1}
============

Human cancer is driven by the acquisition of mutations in cells of somatic origin. Somatic mutations comprise several distinct classes of DNA sequence changes, including single-nucleotide substitutions, small insertions and deletions (indels), copy number alterations, and structural rearrangements ([@bib47]; [@bib5]; [@bib38]; [@bib35]). Somatic mutations can be further characterized based on their oncogenic ability: genetic variations that are directly involved in cancer development are termed "driver" mutations, whereas mutations that do not confer any obvious advantage are referred to as "passenger" mutations ([@bib9]). In all cases, genetic changes in somatic cells arise as a result of defective DNA repair mechanisms and/or imprecise DNA replication, and can develop spontaneously, be acquired over the lifetime of an individual, or by direct exposure to mutagens, such as tobacco smoke and ionizing UV radiation ([@bib34]; [@bib35]; [@bib20]). Over the past 10 years, technologies for the detection of wide-spread genetic alterations have been developed and used to analyze cancer genomes ([@bib38]; [@bib45]). Its is clear that cancer cell genomes often harbor substantial somatic mutation burdens, thus the ability to generate a comprehensive genetic cancer profile has the potential to significantly improve patient diagnosis and treatment.

The combination of PCR and Sanger sequencing to identify mutations in tumor genomes has proven to be a powerful approach in the study of cancer genomics ([@bib7]). However, this technology is constrained by limited throughput and cost ([@bib6]). Here, Kan and colleagues utilized mismatch repair detection (MRD) technology as a low-cost, high throughput alternative to identify somatic mutations in a large number of primary human tumor samples ([@bib33]). Using this technique, Kan and colleagues identified an uncharacterized somatic mutation in *GNAO1* from breast carcinoma tissue ([@bib24]). *GNAO1* encodes the Gαo subunit of heterotrimeric guanine-binding proteins (G proteins) ([@bib22]). G proteins function as molecular switches that alternate between "on" (GTP-bound) and "off" (GDP-bound) states to control signal transduction in eukaryotes ([@bib17]; [@bib3]; [@bib2]). While previous studies have reported oncogenic mutations in the Gα subunits of other G proteins, including *GNAS, GNAI2* and *GNAQ* ([@bib25]; [@bib29]; [@bib15]; [@bib43]), the arginine 243 to histidine (R243H) conversion identified in *GNAO1* does not correspond to any previously described mutations within G proteins ([@bib16]). In Figure 3D--F, the oncogenic potential of this mutation was tested. Human mammary epithelial cells (HMECs) stably expressing equivalent levels of wild type *GNAO1* or *GNAO1*^*R243H*^ were suspended in agar before assessment for colony formation. This key experiment reported that the R243H mutation promotes a two-fold increase in anchorage-independent growth compared to cells expressing wild type *GNAO1*, and will be replicated in Protocol 1. Subsequent work on *GNAO1* has characterized the molecular basis underlying the oncogenic properties of the R243H mutation. Importantly, these studies have determined that the R243H mutation renders Gαo constitutively active via Src-STAT3 signaling ([@bib16]; [@bib26]).

Kan and colleagues also identified a number of somatic mutations in mitogen activated protein kinase kinase 4 (*MAP2K4*) ([@bib24]). MAP2K4 is a component of a triple kinase cascade that involves the successive activation of downstream MAP kinases, culminating in the activation of c-Jun NH2-terminal kinases (JNK) and p38 ([@bib11]; [@bib4]; [@bib23]). Both the JNK and p38 signaling pathways mediate cellular responses to cytokine signals, stress and other extracellular stimuli ([@bib23]). While mutations in *MAP2K4* have been reported here ([@bib24]) and elsewhere ([@bib42]; [@bib31]; [@bib18]; [@bib15]), the role of *MAP2K4* in cancer has remained complex and contradictory. Some studies have suggested *MAP2K4* functions as a pro-oncogenic molecule in breast and pancreatic tumors ([@bib44]), melanoma ([@bib14]), and in prostate cancer tumors ([@bib28]; [@bib32]), whereas other early reports identified *MAP2K4* as a putative tumor suppressor gene due to its frequent inactivation in human cancer cell lines and tumor tissues, including pancreatic, breast, ovarian, and colon cancer cells and tissues ([@bib39]; [@bib40]; [@bib30]; [@bib1]).

In Figure 4C--E, the functional relevance of six select *MAP2K4* mutants (5 located in the kinase domain, 1 outside the kinase domain) were tested *in vitro* ([@bib24]). NIH3T3 fibroblasts stably expressing equivalent levels of either WT or mutant *MAP2K4* were assessed for their ability to promote anchorage-independent growth. Importantly, all six *MAP2K4* variants resulted in significantly enhanced agar colony formation compared to cells expressing wild type *MAP2K4*. A majority of the *MAP2K4* mutants resulted in reduced activity to either JNK or myelin basic protein (MBP) when tested in an *in vitro* kinase assay suggesting that reduced MAP2K4 signaling plays a dominant-negative role in the control of cell growth. A related study examined the invasiveness of cells where endogenous *MAP2K4* was depleted and various *MAP2K4* mutants were added back, including four of the mutants tested by Kan and colleagues ([@bib1]). The effect on invasion was directly proportional to the kinase activities of the mutants. The mutations that resulted in loss-of-function kinase activity (including R154W, S251N, and N234I examined by Kan and colleagues) resulted in increased invasion, while mutations with gain-of-function kinase activity, or comparable kinase activity to wild-type (including A279T examined by Kan and colleagues), did not ([@bib1]). More recent studies have confirmed these findings, showing that *MAP2K4* genetic inactivation is prevalent in high grade serous and endometrioid carcinomas, breast cancer, and pancreatic cancer ([@bib10]; [@bib49]; [@bib48]; [@bib8]; [@bib21]). Furthermore, genetic polymorphisms that increase *MAP2K4* promoter activity are associated with reduced risk of prostate, lung, and sporadic colorectal cancers ([@bib46]; [@bib27]; [@bib37]). A recent study by Haeusgen and colleagues ([@bib19]) suggests that the balance between *MAP2K4* and a novel *MAP2K4 *splice variant may be important in regulating appropriate cell growth. The key experiments described in Figures 4C--F will be replicated in Protocol 2.

Materials and methods {#s2}
=====================

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (\*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (\#) indicates information provided by the replicating lab.

Protocol 1: Generation of N-terminally Flag-tagged *MAP2K4* and *GNAO1* wild-type and mutant vectors {#s2-1}
----------------------------------------------------------------------------------------------------

This protocol generates N-terminally flag-tagged wild type or mutant *GNAO1* and wild type or mutant *MAP2K4* vectors. These vectors will be used in Protocols 2 and 4.

### Sampling {#s2-1-1}

-   This experiment will be performed once in order to generate vectors.

### Materials and reagents {#s2-1-2}

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                                                              Type      Manufacturer   Catalog \#   Comments
  -------------------------------------------------------------------- --------- -------------- ------------ -----------------------------------------
  pRetroX-IRES-ZsGreen1 Vector                                         Plasmid   Clontech       632520       Original product number not specified;\
                                                                                                             replaces pRetro-IRES-GFP-Vector

  *MAP2K4^WT^* Myc-DDK tagged --includes FLAG tag^1^                   Plasmid   Origene        RC206051     Original product number not specified

  *GNAO1^WT^* Myc-DDK tagged (Variant 1) -- includes FLAG tag^1^       Plasmid   Origene        RC217958     Original product number not specified

  Agilent - QuikChange Lightning Multi Site-Directed Mutagenesis Kit   Kit       Agilent        210516       Original product number not specified
  ----------------------------------------------------------------------------------------------------------------------------------------------------

^1^DDK is equivalent to FLAG which is a registered trademark of Sigma Aldrich.

### Procedure {#s2-1-3}

1.  1\. Generate *GNAO1* and *MAP2K4* mutant constructs:Perform site-directed mutations on cDNA ORFs using ^\#^Agilent QuikChange Kit according to manufacturer's protocol.Point mutations:*GNAO1*: arginine 243 to histidine (R243H)*MAP2K4*: arginine 228 to lysine (R228K)*MAP2K4*: alanine 279 to threonine (A279T)

2.  Clone inserts (includes FLAG tag) into ^\#^pRetroX-IRES-ZsGreen1 vector backbone according to manufacturer's protocols.Specific molecular cloning steps and reagents used will be recorded and reported later.^\#^Perform PCR cloning using primers that encompass the ORF and FLAG-tag insert from the original cDNA

3.  Sequence vectors to confirm identity as well as mutational status, and run on gel to confirm integrity. \[additional QC\]^\#^Use the following sequencing primers:*GNAO1^R243H ^*Forward: GCCCTTTTTGAGTTTGGATC*GNAO^R243H^* Reverse: GTAAAGCATGTGCACCGAGG*MAP2K4^R228K^* Forward: GCCCTTTTTGAGTTTGGATC*MAP2K4^R228K^* Reverse: GTAAAGCATGTGCACCGAGG*MAP2K4^A279T^* Forward: GCCCTTTTTGAGTTTGGATC*MAP2K4^A279T^* Reverse: GTAAAGCATGTGCACCGAGG

### Deliverables {#s2-1-4}

-   Data to be collectedSequencing information and gel verification of vectors
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-   Sample delivered for further analysis:Plasmids for use in Protocols 2 and 4:pRetroX-IRES-ZsGreen1pRetroX-FLAG-*GNAO1^WT^*-IRES-ZsGreen1pRetroX-FLAG-*GNAO1^R243H^*-IRES-ZsGreen1pRetroX-FLAG-*MAP2K4^WT^*-IRES-ZsGreen1pRetroX-FLAG-*MAP2K4^R228K^*-IRES-ZsGreen1pRetroX-FLAG-*MAP2K4^A279T^*-IRES-ZsGreen1

### Confirmatory analysis plan {#s2-1-5}

-   None applicable.

### Known differences from the original study {#s2-1-6}

The vector backbone pRetroX-IRES-ZsGreen1 will be used instead of pRetroX-IRES-FLAG because the latter is no longer available. The replicating lab will use a cDNA with an ORF tagged with myc-DDK (the same as FLAG) for downstream protocols. Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-1-7}

Sequencing and gel analysis of plasmids will be reported. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/jpeqg/>) and made publically available.

Protocol 2: Generation of human mammary epithelial cells stably expressing wild-type or GNAO1^R243H^ {#s2-2}
----------------------------------------------------------------------------------------------------

This protocol describes the generation of HMECs stably expressing WT or mutant GNAO1^R243H^ protein. Expression of GNAO1 will be confirmed by Western blot that will be a replication of Figure 3F. These cells will subsequently be used in Protocol 3.

### Sampling {#s2-2-1}

-   This experiment to be conducted one time to confirm stable expression of GNAO1^WT^ or GNAO1^R243H^ protein.

-   The experiment has 4 cohorts:Cohort 1: Uninfected HMECs \[additional negative control\]Cohort 2: HMECs transduced with pRetroX-IRES-ZsGreen1 -empty vector \[additional negative control\]Cohort 3: HMECs transduced with pRetroX-FLAG-*GNAO1^WT^*-IRES-ZsGreen1Cohort 4: HMECs transduced with pRetroX-FLAG-*GNAO1^R243H^*-IRES-ZsGreen1

-   Western blotting will be performed for the following proteins:FLAGβ-ACTIN

### Materials and reagents {#s2-2-2}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                        Type                   Manufacturer                                    Catalog \#      Comments
  ------------------------------ ---------------------- ----------------------------------------------- --------------- -----------------------------------------
  pRetroX-IRES-ZsGreen1 vector   Plasmid                Produced in Protocol 1                                          

  pRetroX- FLAG-*GNAO1^WT^*\     Plasmid                Produced in Protocol 1                                          
  -IRES-ZsGreen1 vector                                                                                                 

  pRetroX-FLAG-*GNAO1^R243H^*\   Plasmid                Produced in Protocol 1                                          
  -IRES-ZsGreen1 vector                                                                                                 

  HMECs                          Cell line              ATCC                                            PCS-600-010     Original product number not specified;\
                                                                                                                        Replaces Life Technology brand used\
                                                                                                                        in original study

  HMEC medium                    Cell culture           ATCC                                            PCS-600-03      Original product number not specified;\
                                                                                                                        Replaces Life Technology brand used\
                                                                                                                        in original study

  HMEC supplement                Cell culture           ATCC                                            PCS-600-040     Original product number not specified;\
                                                                                                                        Replaces Life Technology brand used\
                                                                                                                        in original study

  Bovine pituitary extract       Cell culture           Life Technologies                               13028014        

  Penicillin/Streptomycin        Cell culture           Applied Biological Materials                    G255            Original not specified

  Phoenix amphoteric cells       Cell line              ATCC                                            ATCC CRL-3213   Replaces Orbigen brand\
                                                                                                                        used in original study

  DMEM                           Cell culture           Sigma                                           11965-092       Original not specified

  Fetal bovine serum (FBS)       Cell culture           Life Technologies                               12483-020       Original not specified

  L-glutamine                    Cell culture           Life Technologies                               35050-061       Original not specified

  Glucose                        Cell culture           Life Technologies                               A2494001        Original not specified

  Lipofectamine 2000             Transfection Reagent   Life Technologies                               11668027        

  Opti-MEM                       Transfection Reagent   Sigma-Aldrich                                   31985070        Original not specified

  PBS                            Buffer                 GIBCO                                           10010023        Original not specified

  0.45 µm syringe filter         Labware                Millipore                                       SLHV033RB       Original not specified

  Trypsin EDTA                   Buffer                 ABM                                             TM050           Original not specified

  FBS                            Buffer                 GIBCO                                           12483           Original not specified

  SDS                            Chemical               Left to the discretion of the replicating lab                   

  2-mercaptoethanol              Chemical                                                                               

  Glycerol                       Chemical                                                                               

  bromophenol blue               Chemical                                                                               

  Tris-HCl                       Chemical                                                                               

  Bradford Assay                 Detection assay        Sigma                                           B6916-500 ML    Original not specified

  12% SDS-PAGE gel               Western Blot Reagent   Invitrogen                                      EC60252BOX      Original 4--20%

  OptiProtein Marker             Western Blot Reagent   Applied Biological Materials                    G252            Original not specified

  PVDF membrane                  Western Blot Reagent   Biorad                                          162-0015        Original Nitrocellulose

  Skim milk powder               Western Blot Reagent   Fisher Scientific                               361021617       Original not specified

  1X TBS solution                Buffer                 Fisher Scientific                               BP2471-100      Original not specified

  Anti-FLAG M2 antibody          Antibody               Sigma                                           F1804           

  Anti-ß-ACTIN antibody          Antibody               Abcam                                           Ab8227          Original not specified

  Anti-mouse HRP-conjugated\     Antibody               Abcam                                           Ab6728          Original not specified
  secondary antibody                                                                                                    

  ECL Reagent A and B            Western Blot Reagent   Applied Biological Materials                    G075            Replaces Thermo\
                                                                                                                        Fisher brand.

  X-ray Film                     Western Blot Reagent   Kodak                                           XBT-1           Original not specified
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-2-3}

Notes:

-   HMECs are grown in complete HMEC medium: HMEC medium supplemented with HMEC supplement, ^\#^0.05 mg/mL bovine pituitary extract, 100 U/mL penicillin and 100 mg/ml streptomycin cultured at 37°C and 5% CO~2~.

-   Phoenix cells are grown in complete DMEM medium: DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine and 4.5 g/L glucose, 100 U/mL penicillin and 100 mg/ml streptomycin cultured at 37°C and 5% CO~2~.

-   All cells will be sent for mycoplasma testing and STR profiling.

1.  ^\#^Transfect Phoenix cells with the appropriate retroviral constructs using Lipofectamine 2000 according to manufacturer's instructions.On the day before transfection, transfer Phoenix cells to fresh medium in 6 well plates and maintain at 37°C and 5% CO~2~.On the day of transfection, dilute 2.5 µg plasmid DNA in 500 µl Opti-MEM medium and mix gently.pRetroX-FLAG-*GNAO1^WT^*-IRES-ZsGreen1pRetroX-FLAG-*GNAO1^R243H^*-IRES-ZsGreen1pRetroX-IRES-ZsGreen1 (empty vector)Incubate for 30 min at room temperature.Add DNA-Opti-MEM mixture to 500 µl Lipofectamine 2000.Add DNA-Lipofectamine LTX complex to wells containing Phoenix cells and mix gentlyIncubate cells for 18--48 hr.Change media after 4--6 hr to complete media containing serum.Harvest virus-containing supernatants 48 hr post transfection and re-feed cells with DMEM. Incubate at 37°C in a humidified 5% CO~2~ incubator. Note: Multiple rounds of collection may be required for concentrating stock.This initial collected media can be stored briefly at 4°C.After an additional 12--24 hr of culture, collect viral supernatants again and pool with first collection.^\#^Concentrate viral stock.Centrifuge the viral supernatant at 3000 rpm for 15 min to remove any cell debris.Filter the supernatant through a 0.45 µm syringe filter.Ultracentrifuge at 22,000 rpm for 2 hr at 4°C to produce concentrated viral stocks.Aliquot virus into screw-cap centrifuge tubes and store at -70°C.^\#^Titre retrovirusOne day before harvesting viral supernatant, plate 1.2 × 10^5^ HMECs per well of a 6 well dish.On the day of viral supernatant harvesting, count the number of cells in one well to determine cell number at time of infection.Add a range of volumes between 2 to 5 µl of concentrated viral supernatant to the wells. Incubate for 72 hr.Remove culture medium, wash the wells once with 2 ml PBS.Add 0.5 ml of 0.25% trypsin EDTAIncubate 5 min at 37°C.Add 0.5 ml DMEM-10 or 15 (10--15% FBS).Pipette up and down with 1 ml pipette and transfer cells to a FACS tube.Determine the percentage of GFP-positive cells by FACS analysis.Calculate the number of transfection units (TU/ml):Divide the % GFP-positive cells by 100.Multiply that by the number of cells at the time of infectionDivide that number by the volume of the virus added (ml)This will yield the number of viral particles per ml.Use resulting virus to transduce HMECs in Step 3.

2.  ^\#^One day prior to transduction, seed HMECs in 15 cm plates so they will be 70--90% confluent on the day of transfection.

3.  ^\#^Transduce HMECs with the appropriate viruses (Optimal MOI will be determined prior to transduction).Infect HMECs on a 24-well plate with lentivirus.Cohort 1: Uninfected HMECs \[additional negative control\]Cohort 2: HMECs transduced with pRETRO-IRES-ZsGreen1-empty vector \[additional negative control\]Cohort 3: HMECs transduced with pRETRO-FLAG-*GNAO1^WT^*-IRES- ZsGreen1Cohort 4: HMECs transduced with pRETRO-FLAG-*GNAO1 ^R243H^*-IRES- ZsGreen1After 72 hr, check cells under fluorescence microscope to calculate infection rate.

4.  ^\#^Sterile sort the top 10% of the transduced HMECs by ^\#^flow cytometry based on GFP expression.Trypsinize the cells and resuspend in PBS with 0.5% FBS (FACS buffer)Pass the cells through the cell strainer to make a single cell suspension.Sort cells for GFP signal (top 10% selected) on FACS sorter (Influx 100 μm-18 psi)100,000 cells are collected per tube.

5.  ^\#^Perform Western blots on top 10% GFP positive HMECs to confirm expression of GNAO1:Spin down the cells for 5 min at maximum speed using an eppendorf tube centrifuge. Aspirate and discard the supernatant.Add 100 µl to 200 µl of protein lysis buffer depending on the size of the cell pellet.^\#^Protein lysis buffer: 4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl pH 6.8Quantify protein concentration using a ^\#^Bradford assay according to manufacturer's instructions.Load equal amounts of total protein in 25 µl sample on a ^\#^12% SDS-PAGE gel.Boil for 7 min before loadingLoad one lane with 8 µl protein marker ladder.Run at 150V for 10--15 min.When samples reach separation gel, turn to 100V and run for approximately 1.5 hr. Record running time.Wet transfer to ^\#^PVDF membrane ^\#^at 95V for 70 min.^\#^Block membrane with 3% skim milk in Tris-buffered saline (TBS) on shaker for 30 minIncubate with the following primary antibodies for 1 hr at 37°C:Mouse Anti-FLAG M2 (1:500 dilution)^\#^Mouse Anti-ß-ACTIN (^\#^1:1000 dilution)Wash membrane 3 times in 1X TBS for 5 min each on shaker.Incubate with anti-mouse HRP conjugated secondary antibody (^\#^1:1000) for 1 hr on shaker at room temperature.Remove membrane from secondary antibody and wash three times in 1X TBS for 5 min each.Prepare ECL solution and incubate membrane.Expose membrane to X-ray film, develop and scan.

### Deliverables {#s2-2-4}

-   Data to be collected:Data for viral titrationFlow cytometry data (for viral titration and sorting of transduced cells)Protein determination assay data.Figure 3F: Full scans of all films for each western blot with ladder.

-   Sample delivered for further analysis:HMECs transduced with:pRetroX-IRES-ZsGreen1 (empty vector)pRetroX-FLAG-*GNAO1^WT^*-IRES-ZsGreen1pRetroX-FLAG-*GNAO1^R243H^*-IRES-ZsGreen1

### Confirmatory analysis plan {#s2-2-5}

-   None applicable.

### Known differences from the original study {#s2-2-6}

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-2-7}

The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. GNAO1 expression will be confirmed in the top 10% GFP positive HMECs with western blots. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/jpeqg/>) and made publically available.

Protocol 3: Anchorage-independent colony formation assay of HMECs transduced with wild-type or mutant GNAO1 {#s2-3}
-----------------------------------------------------------------------------------------------------------

This experiment tests the effect of WT or mutant GNAO1 expression on anchorage-independent colony formation of HMECs. It is a replication of the experiments reported in Figure 3D--E.

### Sampling {#s2-3-1}

-   Experiment to be repeated a total of 3 times for a power of 99%.See Power Calculations section for details.

-   Experiment has 4 cohorts:Cohort 1: Uninfected HMECs \[additional negative control\]Cohort 2: HMECs transduced with pRetroX-IRES-ZsGreen1-empty vector \[additional negative control\]Cohort 3: HMECs transduced with pRetroX-FLAG-*GNAO1^WT^*-IRES-ZsGreen1Cohort 4: HMECs transduced with pRetroX-FLAG-*GNAO1^R243H^*-IRES-ZsGreen1

-   Each cohort will have anchorage independent colony formation quantified.

### Materials and reagents {#s2-3-2}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                                      Type           Manufacturer                                    Catalog \#            Comments
  -------------------------------------------- -------------- ----------------------------------------------- --------------------- -----------------------------------------
  HMECs                                        Cell line      ATCC                                            PCS-600-010           Original product number not specified;\
                                                                                                                                    Replaces Life Technology brand used\
                                                                                                                                    in original study

  HMECs transduced with\                       Cell line      Produced in Protocol 2                                                
  pRetroX-IRES-ZsGreen1-empty vector                                                                                                

  HMECs transduced with\                       Cell line      Produced in Protocol 2                                                
  pRetroX-FLAG-*GNAO1^WT^*-IRES-ZsGreen1                                                                                            

  HMECs transduced with\                       Cell line      Produced in Protocol 2                                                
  pRetroX-FLAG-*GNAO1 ^R243H^*-IRES-ZsGreen1                                                                                        

  HMEC medium                                  Cell culture   ATCC                                            PCS-600-03            Replaces Life Technology brand\
                                                                                                                                    used in original study

  HMEC supplement                              Cell culture   ATCC                                            PCS-600-040           Original product number not specified;\
                                                                                                                                    Replaces Life Technology brand used\
                                                                                                                                    in original study

  Bovine pituitary extract                     Cell culture   Life Technologies                               13028014              Originl not specified

  Penicillin/streptomycin                      Cell culture   ABM                                             G255                  Original not specified

  6 well plates                                Labware        Fisher Scientific                               Biolite 12556004      Original not specified

  Low melting temperature agar                 Cell culture   Bioworld                                        40100048-2            Original not specified

  Crystal violet                               Dye            Left to the discretion of the replicating lab   Not originally used   

  Methanol (MeOH)                              Chemical                                                                             

  Acetic acid                                  Chemical                                                                             

  ImageJ                                       Software       NIH                                                                   Replaces Oxford Optronix GelCount\
                                                                                                                                    imager and software
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-3-3}

Notes:

-   Transduced HMECs are generated in Protocol 2.

1.  Grow 3 flasks of transduced and untransduced control HMECs in complete HMEC medium: HMEC medium supplemented with HMEC supplement, ^\#^0.5 mg/mL bovine pituitary extract, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO~2~ (these will be the biological replicates).

2.  Plate a lower layer of ^\#^1 ml 0.5% agar per well in twelve wells of 6-well plates.Let solidify.

3.  Suspend 3 wells each of 3 × 10^4^ HMECs in 1 ml full media containing 0.35% agar containing either:untransduced HMECsHMECs transduced with pRetroX-IRES-ZsGreen1 (empty vector)HMECs transduced with pRetroX-FLAG-*GNAO1^WT^*-IRES-ZsGreen1HMECs transduced with pRetroX-FLAG-*GNAO1^R243H^*-IRES-ZsGreen1

4.  Plate ^\#^1 ml suspended cells on top of the lower layer of 0.5% agar in 6-well plates.

5.  Incubate the plates for 3 weeks at 37°C and 5% CO~2~.^\#^Refresh growth media on top layer every 2--3 days.

6.  Assess the presence of colonies.Stain wells with crystal violet.Remove media from wells.Fix with 500 µl of 10% MeOH/10% acetic acid for 10 min.Remove and stain with 500 µl 0.01% crystal violet for 1 hr.Remove stain and wash wells.Image entire well with high-resolution camera.Include calibration scale in image.Quantify the number of colonies greater than 200 µm in diameter using ImageJ software.Set threshold using calibration scale taken during image acquisition.

### Deliverables {#s2-3-4}

-   Data to be collected:Figure 3D: Images of colonies.Raw numbers for quantification of colonies for each sample.Figure 3E: Graph of mean number of colonies for each cohort.

### Confirmatory analysis plan {#s2-3-5}

-   Statistical Analysis of the Replication Data:

-   Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.Unpaired two-tailed *t*-test of the mean number of colonies in HMECs expressing exogenous GNAO1^WT^ or GNAO1^R243H^.

-   Meta-analysis of original and replication attempt effect sizes:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot

### Known differences from the original study {#s2-3-6}

The original study counted cell colonies using GelCount to image, count, and analyze colonies, while the replication attempt will stain with crystal violet to enhance detection of cell colonies, image wells with a high-resolution camera, and use ImageJ software to count and analyze colonies. Since the software and approach used by the original and replication attempt are different, there will likely be some differences in sensitivity and error rates. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-3-7}

The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/jpeqg/>) and made publically available.

Protocol 4: Generation of NIH3T3 cells stably expressing wild-type or mutant MAP2K4 {#s2-4}
-----------------------------------------------------------------------------------

This protocol describes the generation of NIH3T3 cells stably expressing wild-type or mutant MAP2K4 proteins. This protocol also describes verification of expression of MAP2K4 by western blot that will be a replication of Figure 4E. These cells will subsequently be used in Protocols 4 and 5.

### Sampling {#s2-4-1}

-   This experiment will be conducted one time to confirm stable expression of exogenous MAP2K4.

-   Experiment has 5 cohorts:Cohort 1: Uninfected NIH3T3 cells \[additional negative control\]Cohort 2: transduced with pRetroX-IRES-ZsGreen1 (empty vector)Cohort 3: transduced with pRetroX-FLAG-*MAP2K4^WT^*-IRES-ZsGreen1Cohort 4: transduced with pRetroX-FLAG-*MAP2K4^R228K^*-IRES-ZsGreen1Cohort 5: transduced with pRetroX-FLAG-*MAP2K4^A279T^*-IRES-ZsGreen1

-   To confirm MAP2K4 expression, Western blotting will be performed for the following proteins:FLAGβ-ACTIN \[Additional loading control\]

### Materials and reagents {#s2-4-2}

  --------------------------------------------------------------------------------------------------------------------------------------
  Reagent                          Type                   Manufacturer                   Catalog \#      Comments
  -------------------------------- ---------------------- ------------------------------ --------------- -------------------------------
  NIH3T3 cells                     Cell line              ATCC                           CRL-1658        

  DMEM medium                      Cell culture           Sigma                          11965-092       Original not specified

  FBS                              Cell culture           Life Technologies              12483-020       Original not specified

  L-glutamine                      Cell culture           Life Technologies              35050-061       Original not specified

  Penicillin/Streptomycin          Cell culture           Applied Biological Materials   G255            Original not specified

  pRetroX-IRES-ZsGreen1 vector     Plasmid                Produced in Protocol 1                         

  pRetroX-FLAG-*MAP2K4^WT^*-\      Plasmid                Produced in Protocol 1                         
  IRES-ZsGreen1 vector                                                                                   

  pRetroX-FLAG-*MAP2K4^R228K^*-\   Plasmid                Produced in Protocol 1                         
  IRES-ZsGreen1 vector                                                                                   

  pRetroX-FLAG-*MAP2K4^A279T^*-\   Plasmid                Produced in Protocol 1                         
  IRES-ZsGreen1 vector                                                                                   

  Phoenix amphoteric cells         Cell line              ATCC                           ATCC CRL-3213   Replaces Orbigen\
                                                                                                         brand used in original study

  Lipofectamine 2000               Transfection Reagent   Life Technologies              11668027        

  Opti-MEM                         Transfection Reagent   Sigma-Aldrich                  31985070        Original not specified

  PBS                              Buffer                 GIBCO                          10010023        Original not specified

  0.45 µm syringe filter           Labware                Millipore                      SLHV033RB       Original not specified

  Trypsin EDTA                     Buffer                 ABM                            TM050           Original not specified

  FBS                              Buffer                 GIBCO                          12483           Original not specified

  SDS                              Chemical                                                              

  2-mercaptoethanol                Chemical                                                              

  Glycerol                         Chemical                                                              

  bromophenol blue                 Chemical                                                              

  Tris-HCl                         Chemical                                                              

  Bradford Assay                   Detection assay        Sigma                          B6916-500 ML    Original not specified

  12% SDS-PAGE gel                 Western Blot Reagent   Invitrogen                     EC60252BOX      Original 4--20%

  OptiProtein Marker               Western Blot Reagent   Applied Biological Materials   G252            Original not specified

  PVDF membrane                    Western Blot Reagent   Biorad                         162-0015        Original Nitrocellulose

  1X TBS solution                  Buffer                 Fisher Scientific              BP2471-100      Original not specified

  Anti-FLAG M2 antibody            Antibody               Sigma                          F1804           

  Anti-ß-ACTIN antibody            Antibody               Abcam                          Ab8227          Original not specified

  Anti-mouse HRP-conjugated\       Antibody               Abcam                          Ab6728          Original not specified
  secondary antibody                                                                                     

  ECL Reagent A and B              Western Blot Reagent   Applied Biological Materials   G075            Replaces Thermo Fisher brand.

  X-ray Film                       Western Blot Reagent   Kodak                          XBT-1           Original not specified
  --------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-4-3}

Notes:

-   NIH3T3 cells are grown in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO~2~.

-   Phoenix cells grown in complete DMEM medium: DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO~2~.

-   All cells will be sent for mycoplasma testing and STR profiling.

1.  Transfect Phoenix cells with the appropriate constructs as in Protocol 2 step 1.

2.  Transduce NIH3T3 cells with the appropriate viruses as in Protocol 2 steps 2 and

3.  Sterile sort the top 10% of the transduced NIH3T3 cells by flow cytometry based on GFP expression as in Protocol 2 Step 4.

4.  Perform western blot on sorted cells to confirm expression of MAP2K4 as in Protocol 2 Step 5.

### Deliverables {#s2-4-4}

-   Data to be collected:Data for viral titrationFlow cytometry data (for viral titration and sorting of transduced cells)Protein determination assay data.Figure 4E: Full scans of all films for each western with ladder.

-   Sample delivered for further analysis:NIH3T3 cells transduced with:pRetroX-IRES-ZsGreen1 (empty vector)pRetroX-FLAG-*MAP2K4^WT^*-IRES-ZsGreen1pRetroX-FLAG-*MAP2K4^R228K^*-IRES-ZsGreen1pRetroX-FLAG-*MAP2K4^A279T^*-IRES-ZsGreen1

### Confirmatory analysis plan {#s2-4-5}

-   None applicable.

### Known differences from the original study {#s2-4-6}

Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-4-7}

The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. MAP2K4 expression will be confirmed in the top 10% GFP positive HMECs with Western blots. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/jpeqg/>) and made publically available.

Protocol 5: Anchorage-independent colony formation assay of NIH3T3 cells transduced with wild-type or mutant MAP2K4 {#s2-5}
-------------------------------------------------------------------------------------------------------------------

This experiment tests the effect of WT or mutant MAP2K4 expression on anchorage-independent colony formation of NIH3T3 cells. It is a replication of the experiments reported in Figure 4C and 4D.

### Sampling {#s2-5-1}

-   Experiment to be repeated a total of 3 times for a minimum power of 99%.See Power Calculations section for details.

-   Experiment has 5 (generated in Protocol 4) cohorts:Cohort 1: Uninfected NIH3T3 cells \[additional negative control\]Cohort 2: NIH3T3 cells transduced with with pRetroX-IRES-ZsGreen1-empty vectorCohort 3: NIH3T3 cells transduced with with pRetroX-FLAG-*MAP2K4^WT^*-IRES-ZsGreen1Cohort 4: NIH3T3 cells transduced with with pRetroX-FLAG-*MAP2K4^R228K^*-IRES-ZsGreen1Cohort 5: NIH3T3 cells transduced with with pRetroX-FLAG-*MAP2K4^A279T^*-IRES-ZsGreen1

-   Each cohort will have anchorage independent colony formation quantified.

### Materials and reagents {#s2-5-2}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                                      Type           Manufacturer                                     Catalog \#            Comments
  -------------------------------------------- -------------- ------------------------------------------------ --------------------- ------------------------------------
  NIH3T3 cells transduced with\                Cell line      Produced in Protocol 4                                                 
  pRetroX-IRES-ZsGreen1-empty vector                                                                                                 

  NIH3T3 cells transduced with\                Cell line      Produced in Protocol 4                                                 
  pRetroX-FLAG-*MAP2K4^WT^*-IRES-ZsGreen1                                                                                            

  NIH3T3 cells transduced with\                Cell line      Produced in Protocol 4                                                 
  pRetroX-FLAG-*MAP2K4^R228K^*-IRES-ZsGreen1                                                                                         

  NIH3T3 cells transduced with\                Cell line      Produced in Protocol 4                                                 
  pRetroX-FLAG-*MAP2K4^A279T^*-IRES-ZsGreen1                                                                                         

  DMEM medium                                  Cell culture   Sigma                                            11965-092             Original not specified

  FBS                                          Cell culture   Life Technologies                                12483-020             Original not specified

  L-glutamine                                  Cell culture   Life Technologies                                35050-061             Original not specified

  Penicillin/streptomycin                      Cell culture   Applied Biological Materials                     G255                  Original not specified

  6 well plates                                Labware        Fisher Scientific                                Biolite 12556004      Original not specified

  Low melting temperature agar                 Cell culture   Bioworld                                         40100048-2            Original not specified

  Crystal violet                               Dye            Left to the discretion of the replicating lab\   Not originally used   

  Methanol (MeOH)                              Chemical                                                                              

  Acetic acid                                  Chemical                                                                              

  ImageJ                                       Software       NIH                                                                    Replaces Oxford Optronix GelCount\
                                                                                                                                     imager and software
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-5-3}

Note:

-   All cells will be sent for mycoplasma testing and STR profiling.

1.  Grow 3 flasks each of transduced NIH3T3 cells generated in Protocol 4 in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin cultured at 37°C and 5% CO~2~. (these will be the biological replicates)

2.  Plate a lower layer of ^\#^1 ml 0.5% agar per well in 16 wells of 6-well plates.Let solidify.

3.  Suspend 3 plates each of 1 × 10^4^ cells/plate in 1 ml full media containing 0.35% agar containing either:uninfected NIH3T3 cells \[additional negative control\]NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1-empty vectorNIH3T3 cells transduced with pRetroX-FLAG-*MAP2K4^WT^*-IRES-ZsGreen1NIH3T3 cells transduced with pRetroX-FLAG-*MAP2K4^R228K^*-IRES-ZsGreen1NIH3T3 cells transduced with pRetroX-FLAG-*MAP2K4^A279T^*-IRES-ZsGreen1

4.  Plate ^\#^1 ml suspended cells on top of the lower layer of 0.5% agar in 6-well plates.

5.  Incubate the plates for 3 weeks at 37°C and 5% CO~2~.^\#^Refresh growth media from top layer every 2--3 days.

6.  Assess the presence of colonies.Stain wells with crystal violet.Remove media from wells.Fix with 500 µl of 10% MeOH/10% acetic acid for 10 min.Remove and stain with 500 µl 0.01% crystal violet for 1 hr.Remove stain and wash wells.Image entire well with a high-resolution camera.Include calibration scale in image.Quantify the number of colonies greater than 100 µm in diameter using ImageJ software.Set threshold using scale taken during image acquisition.

### Deliverables {#s2-5-4}

-   Data to be collected:Figure 4C: Images of colonies.Raw numbers for quantification of colonies for each sample.Figure 4D: Graph of mean number of colonies for each cohort.

### Confirmatory analysis plan {#s2-5-5}

-   Statistical Analysis of the Replication Data:

-   Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.One-way ANOVA of the mean number of colonies in NIH3T3 cells expressing exogenous MAP2K4^WT^, MAP2K4^R228K^, or MAP2K4^A279T^ followed by planned comparisons using Fisher's LSD:MAP2K4^WT^ vs MAP2K4^R228K^MAP2K4^WT^ vs MAP2K4^A279T^

-   Meta-analysis of original and replication attempt effect sizes:Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-5-6}

Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. The original study counted cell colonies using GelCount to image, count, and analyze colonies, while the replication attempt will stain with crystal violet to enhance detection of cell colonies, image wells with a high-resolution camera, and use ImageJ software to count and analyze colonies. Since the software and approach used by the original and replication attempt are different, there will likely be some differences in sensitivity and error rates. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-5-7}

The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/jpeqg/>) and made publically available.

Protocol 6: Assessing the kinase activity of wild-type or mutant MAP2K4 {#s2-6}
-----------------------------------------------------------------------

This experiment tests the *in vitro* kinase activity of WT or mutant MAP2K4 immunoprecipitated from NIH3T3 cells. It is a replication of the experiment reported in Figure 4F.

### Sampling {#s2-6-1}

-   Experiment to be repeated a total of 4 times.The original data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes were determined based on a range of potential variance.See Power Calculations section for details.

-   Experiment has 5 cohorts:Cohort 1: Uninfected NIH3T3 cells \[additional negative control\]Cohort 2: NIH3T3 cells transduced with pRetroX-IRES-ZsGreen1 (empty vector)Cohort 3: NIH3T3 cells transduced with pRetroX-FLAG-*MAP2K4^WT^*-IRES-ZsGreen1Cohort 4: NIH3T3 cells transduced pRetroX-FLAG-*MAP2K4^R228K^*-IRES-ZsGreen1Cohort 5: NIH3T3 cells transduced with pRetroX-FLAG-*MAP2K4^A279T^*-IRES-ZsGreen1

-   A kinase assay is performed for each cohort using the following substrates:Myelin basic protein (MBP)Inactive MAPK9/JNK2

### Materials and reagents {#s2-6-2}

  --------------------------------------------------------------------------------------------------------------------------------------
  Reagent                              Type                   Manufacturer                   Catalog \#     Comments
  ------------------------------------ ---------------------- ------------------------------ -------------- ----------------------------
  NIH3T3 cells transduced with\        Cell line              Produced in Protocol 4                        
  pRetroX-IRES-ZsGreen1-empty vector                                                                        

  NIH3T3 cells transduced with\        Cell line              Produced in Protocol 4                        
  pRetroX-FLAG-*MAP2K4^WT^*-\                                                                               
  IRES-ZsGreen1                                                                                             

  NIH3T3 cells transduced with\        Cell line              Produced in Protocol 4                        
  pRetroX-FLAG-*MAP2K4^R228K^*-\                                                                            
  IRES-ZsGreen1                                                                                             

  NIH3T3 cells transduced with\        Cell line              Produced in Protocol 4                        
  pRetroX-FLAG-*MAP2K4^A279T^*-\                                                                            
  IRES-ZsGreen1                                                                                             

  DMEM medium                          Cell culture           Sigma                          11965-092      Original not specified

  FBS                                  Cell culture           Life Technologies              12483-020      Original not specified

  L-glutamine                          Cell culture           Life Technologies              35050-061      Original not specified

  EZview FLAG-M2-antibody-coupled\     Chromatography         Sigma                          A2220          
  affinity gel                                                                                              

  Penicillin/streptomycin              Cell culture           Applied Biological Materials   G255           Original not specified

  Cell Lysis Buffer                    Buffer                 Cell Signaling Technology      9803           Original product number\
                                                                                                            not specified

  Phenylmethanesulfonyl\               Protease inhibitor     Cell Signaling Technology      8853           Original not specified
  Fluoride (PMSF)                                                                                           

  Myelin basic protein                 Protein                Signalchem                     M42-51N        Replaces Millipore AB15542

  Inactive MAPK9/JNK2                  Protein                Invitrogen                     PV3621         Listed as MAP2K7 in\
                                                                                                            original paper.

  \[γ-32P\]ATP                         Chemical               Perkin Elmer                   BLU002H250UC   

  Kinase Reaction Buffer               Buffer                 Cell Signaling Technology      9802           Original product number\
                                                                                                            not specified

  Anti-FLAG M2 Magnetic Beads          Kinase assay reagent   Sigma-Aldrich                  M8823          Original not specified

  12% SDS-PAGE                         Western Blot Reagent   Invitrogen                     EC60252BOX     Original 4--20%

  Bradford Assay                       Detection assay        Sigma                          B6916-500 ML   Original not specified

  OptiProtein Marker                   Western Blot Reagent   Applied Biological Materials   G252           Original not specified

  PVDF membrane                        Western Blot Reagent   Biorad                         162-0015       Original Nitrocellulose

  Skim milk powder                     Western Blot Reagent   Fisher Scientific              361021617      Original not specified

  1X TBS solution                      Buffer                 Fisher Scientific              BP2471-100     Original not specified

  Anti-FLAG M2 antibody                Antibody               Sigma                          F1804          

  Anti-ß-ACTIN antibody                Antibody               Abcam                          Ab8227         Original not specified

  Anti-mouse HRP-conjugated\           Antibody               Abcam                          Ab6728         Original not specified
  secondary antibody                                                                                        

  ECL Reagent A and B                  Western Blot Reagent   Applied Biological Materials   G075           Replaces Thermo\
                                                                                                            Fisher brand.

  X-ray Film                           Western Blot Reagent   Kodak                          XBT-1          Original not specified
  --------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-6-3}

Note:

-   Transduced NIH3T3 cells are generated in Protocol 4.

-   All cells will be sent for mycoplasma testing and STR profiling.

1.  Grow 4 flasks of NIH3T3 in complete DMEM medium: DMEM medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin cultured at 37°C and 5% CO~2~. These are the biological replicates.

2.  Generate cell lysates:Plate cells for kinase assay so they will be 70--90% confluent on the day of harvest.Replace with serum free media (0% FBS) and serum starve cells for 24 hr.Wash cells with PBS and lyse with Cell Lysis Buffer (with 1 mM PMSF added just before use).Clarify lysates.Quantify protein concentration using a Bradford Assay according to manufacturer's instructions.Adjust samples to equalize for total amount of protein and concentration.

3.  Perform immunoprecipitation:Incubate clarified lysates with anti-FLAG-M2 conjugated beads overnight at 4°C.Spin beads down at 10,000x*g* for 30 s, remove supernatant and wash three times with Cell lysis buffer (with 1 mM PMSF added just before use).Remove sample for input analysis and divide sample equally between two microcentrifuge tubes.Spin beads down and remove supernatant.

4.  Kinase AssayAdd 25 µl of Kinase Reaction Buffer supplemented with 10 µM ATP and 2 µCi \[γ-32P\]ATP with either:Myelin basic protein (MBP) (^\#^1:2000)Inactive MAPK9/JNK2 (^\#^1:2000).Incubate samples for 30 min at 30°C.Stop kinase reactions by adding SDS sample buffer.Resolve kinase reactions on ^\#^15% SDS-PAGE gel with protein ladder.^\#^Fix gel for 15 min in 5% methanol, 7% acetic acid and dry at 60°C for 30 min.Expose gel to X-ray film and scan images.

5.  Perform western blot on input sample for MAP2K4 expression as in Protocol 2 Step 5.

6.  For each replicate normalize each protein (MBP and MAPK9/JNK2) to MAP2K4 input levels and then normalize each sample to MAP2K4^WT^.

### Deliverables {#s2-6-4}

-   Data to be collected:Protein determination assay data.Figure 4F: Full images of autoradiographs for each kinase assay substrate with ladder.Figure 4F: Scans of full films for western blot of MAP2K4 input with ladder.

### Confirmatory analysis plan {#s2-6-5}

-   Statistical Analysis of the Replication Data:

-   Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.Bonferroni corrected one-sample *t*-tests of normalized pMBP levels from the following MAP2K4 variants compared to 1 (MAP2K4^WT^):MAP2K4^R228K^MAP2K4^A279T^Bonferroni corrected one-sample *t*-tests of normalized pMAPK9/pJNK levels from the following MAP2K4 variants compared to 1 (MAP2K4^WT^):MAP2K4^R228K^MAP2K4^A279T^

-   Meta-analysis of effect sizes:Since some of the band intensities in the original paper were unable to be quantified the replication study will record and make accessible all autoradiographs collected. This will allow for a subjective comparison of the original images and the replication images. Additionally, the replication will quantify the results in an additional exploratory measure. This cannot be compared to the original reported results, but will be presented to understand the utility of analyzing the data in a quantitative manner.

### Known differences from the original study {#s2-6-6}

Not all mutants used in the original study will be replicated. We will not generate MAP2K4 mutations G85R, R154W, N234I or S251N. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-6-7}

The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/jpeqg/>) and made publically available.

Power calculations {#s3}
==================

For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:

<https://osf.io/bxr2d/>

Protocol 1: {#s3-1}
-----------

-   Not applicable

Protocol 2: {#s3-2}
-----------

-   Not applicable

Protocol 3: {#s3-3}
-----------

### Summary of original data {#s3-3-1}

-   Note; values are from data shared by authors, which was reported in Figure 3E.

  Vector   Mean \# of colonies \>200 μm diameter   Stdev    N
  -------- --------------------------------------- -------- ---
  WT       113.5                                   10.607   2
  R243H    201.5                                   16.263   2

### Test family {#s3-3-2}

-   Two-tailed *t* test, difference between two independent means, alpha error = 0.050

### Power calculations {#s3-3-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib13]).

  Group 1   Group 2   Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  --------- --------- ----------------- ---------------- --------------------- ---------------------
  WT        R243H     6.40954           87.2%^1,2^       2^1^                  2^1^

^1^ 3 samples per group will be used making the achieved power of 99.9%.

^2^ The calculation was also performed with the non-parametric Wilcoxon-Mann-Whitney test, which gives an achieved power of 99.9% with a sample size of 3 per group.

Protocol 4: {#s3-4}
-----------

-   Not applicable

Protocol 5: {#s3-5}
-----------

### Summary of original data {#s3-5-1}

-   Note: values are from data shared by authors, which was reported in Figure 4D:

  Vector   Mean \# of colonies \>100 μm diameter   Stdev    N
  -------- --------------------------------------- -------- ---
  WT       16                                      2.8284   2
  R228K    36                                      2.8284   2
  A279T    94.5                                    7.7782   2

### Test family {#s3-5-2}

-   ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05

### Power calculations {#s3-5-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib13]).

-   ANOVA F test statistic and partial η^2^ performed with R software, version 3.1.2 ([@bib41]).

  -------------------------------------------------------------------------------------------------------------------------
  Groups                          F test statistic    Partial η^2^   Effect size *f*   A priori power   Total sample size
  ------------------------------- ------------------- -------------- ----------------- ---------------- -------------------
  NIH3T3 cells transduced with\   F~(2,3)~ = 130.52   0.98864        9.3280            99.9%            6^1^\
  WT or *MAP2K4* mutants                                                                                (3 groups)

  -------------------------------------------------------------------------------------------------------------------------

^1^9 total samples (3 per group) will be used as a minimum sample size making the power 99.9%.

### Test family {#s3-5-4}

-   Two-tailed *t* test, difference between two independent means, Fisher's LSD: alpha error = 0.05

### Power calculations {#s3-5-5}

-   Performed with G\*Power software, version 3.1.7 ([@bib13]).

  Group 1   Group 2   Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  --------- --------- ----------------- ---------------- --------------------- ---------------------
  WT        R228K     7.07107           99.9%^1,2^       2^1^                  2^1^
  WT        A279T     13.4134           99.9%^1,2^       2^1^                  2^1^

^1^ 3 samples per group will be used making the power 99.9%.

^2^ The calculation was also performed with the non-parametric Wilcoxon-Mann-Whitney test, which gives an achieved power of 99.9% with a sample size of 3 per group.

Protocol 6 {#s3-6}
----------

### Summary of original data {#s3-6-1}

-   Note: data estimated from the image reported in Figure 4F.The original data presented is qualitative (images of Western blots). We used ImageJ version 1.50a ([@bib36]) to perform densitometric analysis of the presented bands to quantify the original effect size where possible. The data presented in Figure 4F for Input MAP2K4 were unable to be quantified for all bands and were thus excluded from the normalization. Additionally, the WT values provide under-estimates of the actual values since the WT bands were saturated and unable to be quantified.

  Variant   Normalized pJNK band intensity to WT   Normalized pMBP band intensity to WT
  --------- -------------------------------------- --------------------------------------
  WT        1                                      1
  R228K     0.299736                               0.057556
  A279T     0.613378                               0.096804

-   The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.

### Test family {#s3-6-2}

-   *t*-test: Means: Difference from constant (one sample case): Bonferroni's correction: alpha error = 0.0125.

### Power calculations {#s3-6-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib13]).

-   2% variance

  Substrate   Variant   Constant (WT)   Effect size *d*   A priori power   Sample size per group
  ----------- --------- --------------- ----------------- ---------------- -----------------------
  P-JNK       R228K     1               116.813           99.9%            3
  A279T       1         31.5157         99.9%             3                
  P-MBP       R228K     1               818.713           99.9%            3
  A279T       1         466.507         99.9%             3                

-   15% variance

  Substrate   Variant   Constant (WT)   Effect size *d*   A priori power   Sample size per group
  ----------- --------- --------------- ----------------- ---------------- -----------------------
  P-JNK       R228K     1               15.5751           99.9%            3
  A279T       1         4.20210         92.2%             4                
  P-MBP       R228K     1               109.162           99.9%            3
  A279T       1         62.2009         99.9%             3                

-   28% variance

  Substrate   Variant   Constant (WT)   Effect size *d*   A priori power   Sample size per group
  ----------- --------- --------------- ----------------- ---------------- -----------------------
  P-JNK       R228K     1               8.34380           92.6%            3
  A279T       1         2.25112         88.7%             6                
  P-MBP       R228K     1               58.4795           99.9%            3
  A279T       1         33.3219         99.9%             3                

-   40% variance

  Substrate   Variant   Constant (WT)   Effect size *d*   A priori power   Sample size per group
  ----------- --------- --------------- ----------------- ---------------- -----------------------
  P-JNK       R228K     1               5.84066           99.5%            4
  A279T       1         1.57579         82.5%             8                
  P-MBP       R228K     1               40.9357           99.9%            3
  A279T       1         23.3254         99.9%             3                

-   Based on these ranges of variance, which use a conservative effect size estimate since the original data were unable to be quantified, we will run the experiment four times.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers\" for consideration by *eLife*. Your submission has been evaluated by a Senior Editor, who would like you to revise the article as follows prior to peer review:

1\) In the case of MAP2K4 there has been independent validation by others that the mutants lack kinase activity, and can drive transformation. In this regard, the authors have missed an important paper (Ahn et al. MCB 31:4270), where the authors examined the properties of 11 MAP2K4 cancer mutants for kinase activity and their ability to affect cell migration and invasion in culture, and alter autochthonous mutant KRas driven NSCLC tumor growth in vivo, reaching the conclusion that MAP2K4 acts as a tumor suppressor. We suggest that the authors add discussion of the Ahn et al. paper and review the literature on MAP2K4 mutations both prior to and subsequent to the Kan et al. paper in question, comprehensively, to ensure that there aren\'t any other omissions.

2\) A technical issue relates to the authors\' proposed use of inactive MAP2K7/JNK2 as a substrate for the in vitro MAP2K4 kinase assay. MAP2K7 (aka MKK7) is not the same as JNK2, and it is not a substrate for MAP2K4. This notation came from the original Kan et al. paper, but I suspect they mean MAPK9/JNK2, which is what the Invitrogen website lists under the PV3621 catalogue number they give. Could you check and correct this accordingly?

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for submitting your work entitled \"Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Tony Hunter as the Senior Editor and Reviewing Editor. Two of the three reviewers, Somasekar Seshagiri and John Brognard, have agreed to share their names.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

As part of the Reproducibility Project: Cancer Biology, the authors will set out to replicate experimental data on mutant forms of GNAO1 and MAP2K4 that were published in Kan et al. (Nature 2010). The authors note that the functional relevance of the mutant forms of GNAO1 and MAP2K4 in cancer has been established by subsequent studies and propose to replicate the colony formation assay and kinase assay (MAP2K4) experiments reported in Kan et al. (Nature 2010). The authors describe the reagent generation, experimental work and analysis in great detail. The reviewers agree that the proposed plan is appropriate and closely adheres to published methods, but we have the following requests for revisions before publication of the Registered Report.

Essential revisions:

In the Registered Report, the authors use six protocols to replicate the experiments. For protocol 3, 5 and 6 power calculations and confirmatory analysis plans are described. In the confirmatory analysis plan of the protocol five One-way Anova is followed by planned comparisons using Fisher\'s LSD and in the corresponding power calculations for the t-tests a 0.05 α error is used. Fisher\'s LSD, however, does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. A Bonferroni correction should be used (α = 0.025. This issue needs to be addressed.

Reference: Anthony J Hayter. The maximum familywise error rate of Fisher\'s least significant difference test. Journal of the American Statistical Association, 81(396): 1000-1004, 1986. doi: 10.1080/01621459.1986.10478364

10.7554/eLife.11566.003

Author response

*1) In the case of MAP2K4 there has been independent validation by others that the mutants lack kinase activity, and can drive transformation. In this regard, the authors have missed an important paper (Ahn et al. MCB 31:4270), where the authors examined the properties of 11 MAP2K4 cancer mutants for kinase activity and their ability to affect cell migration and invasion in culture, and alter autochthonous mutant KRas driven NSCLC tumor growth* in vivo*, reaching the conclusion that MAP2K4 acts as a tumor suppressor. We suggest that the authors add discussion of the Ahn* et al.

*paper and review the literature on MAP2K4 mutations both prior to and subsequent to the Kan et al. paper in question, comprehensively, to ensure that there aren\'t any other omissions.*

We have incorporated a discussion of this study (Ahn et al. 2011) into the Introduction. We have also added other citations to expand the state of knowledge about the function of MAP2K4 mutations.

*2) A technical issue relates to the authors\' proposed use of inactive MAP2K7/JNK2 as a substrate for the* in vitro *MAP2K4 kinase assay. MAP2K7 (aka MKK7) is not the same as JNK2, and it is not a substrate for MAP2K4. This notation came from the original Kan et al. paper, but I suspect they mean MAPK9/JNK2, which is what the Invitrogen website lists under the PV3621 catalogue number they give. Could you check and correct this accordingly?*

We have made this change. The Invitrogen PV3621 MAPK9 is listed correctly listed in the reagents list.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Essential revisions: In the Registered Report, the authors use six protocols to replicate the experiments. For protocol 3, 5 and 6 power calculations and confirmatory analysis plans are described. In the confirmatory analysis plan of the protocol five One-way Anova is followed by planned comparisons using Fisher\'s LSD and in the corresponding power calculations for the t-tests a 0.05 α error is used. Fisher\'s LSD, however, does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. A Bonferroni correction should be used (α

*= 0.025. This issue needs to be addressed. Reference: Anthony J Hayter. The maximum familywise error rate of Fisher\'s least significant difference test. Journal of the American Statistical Association, 81(396): 1000-1004, 1986. doi: 10.1080/01621459.1986.10478364*

We agree with the reviewers' comment on the use of a correction, such as Bonferroni or the modification of LSD by Hayter as ways to control for the MFWER; however as Hayter describes in his 1986 paper, this applies in situations where the ANOVA is unbalanced or with a balanced design with four or more populations. Since the proposed analysis is balanced with three population groups, the LSD is sufficiently conservative and powerful to account for the multiple comparisons in this specific situation. This is further explained by Levin et al., 1994 and discussed in Maxwell and Delaney, 2004 (Chapter 5) and Cohen, 2001 (Chapter 12).
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